A 2-year pilot RCT (PMID: 41770546) suggests that low-dose lithium carbonate is feasible and safe for older adults with Mild Cognitive Impairment (MCI).
While primary outcomes did not reach significance, a trend toward slower decline in verbal memory (CVLT-II) was observed (P = .05), suggesting a potential cognitive signal.
Lithium’s role is being re-evaluated alongside emerging disease-modifying therapies like lecanemab and novel multisystem targets such as GPR3 and the gut-brain axis.
Advanced machine learning and multimodal modeling (PMID: 41376794) are essential for identifying MCI subgroups likely to benefit from neuroprotective agents like lithium.
Background
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.